1,721,019 research outputs found
From pro-re-nata to fixed-interval regimen: evolving real-world treatment paradigms in anti-VEGF therapy for neovascular AMD
No full textObjective: To evaluate the impact of evolving treatment paradigms for neovascular age-related macular degeneration (nAMD) by comparing outcomes between two patient cohorts treated with different anti-vascular endothelial growth factor (anti-VEGF) regimens over a decade apart. Methods: This retrospective cohort study included 200 treatment-naive nAMD patients divided into two cohorts. Cohort 1 (2009–2010) was treated with a pro re nata (PRN) regimen, involving three initial monthly injections followed by as-needed treatments based on monthly monitoring. Cohort 2 (2019–2021) received a fixed-interval regimen, consisting of three initial monthly injections followed by bimonthly maintenance doses. Primary outcomes included changes in best corrected visual acuity (BCVA) and central retinal thickness (CRT) at 12 months. Secondary outcomes included the number of injections, follow-up visits, and adherence to treatment schedules. Results: Cohort 2 demonstrated significantly greater improvement in BCVA (+5.5 vs −2.0 ETDRS letters, p < 0.001) and CRT reduction (−101.7 vs −26.5 μm, p < 0.001) compared to Cohort 1. Patients in Cohort 2 received more injections (7.7 vs 4.8, p < 0.001) but required fewer monitoring visits (3.2 vs 5.1, p < 0.001). Adherence to treatment schedules was markedly higher in Cohort 2 (78% vs 0%, p < 0.001). Conclusions: The transition from a PRN to a fixed-interval anti-VEGF regimen significantly improved visual and anatomical outcomes in nAMD patients. Fixed-interval regimens not only enhanced treatment efficacy but also optimized resource utilization, suggesting a superior approach for managing nAMD in a real-world clinical setting
INTRAVITREAL DEXAMETHASONE IMPLANT FOR THE TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA UNRESPONSIVE TO ANTI-VEGF THERAPY
No full textChoriocapillaris and outer choroid blood flow in acute central serous chorioretinopathy: a swept source OCT angiography study
No full textDoes the presence of vitreo-macular adhesion influence the outcome of antivascular endothelial growth factor therapy in patients with neovascular agerelated macular degeneration? Systematic review and meta-analysis
No full textTwelve-month treatment with intravitreal dexamethasone implant for diabetic macular edema
No full textScreening performance of an automated image analysis software for the detection of diabetic retinopathy using a conventional fundus photography or a confocal white LED device: a comparison study
No full textRanibizumab in neovascular age-related macular degeneration: an as-needed treatment regimen with bimonthly evaluation
No full textExtended duration of VEGF inhibition with aflibercept 8 mg: the role of reduced ocular clearance
No full textKey messages: What is known • Anti-VEGF therapy is the cornerstone of neovascular AMD treatment, but frequent intravitreal injections are required due to the short half-life and rapid ocular clearance of these agents. What is new • The newly available 8 mg aflibercept formulation exhibits a 34.4% slower ocular clearance compared to the standard 2 mg dose, exceeding predictions based on a simple dose increase. • Pharmacokinetic modeling demonstrates that this reduced clearance extends VEGF suppression duration up to 20 weeks, aligning with clinical outcomes from the PULSAR trial. • The enhanced durability of aflibercept 8 mg appears to be driven by formulation differences, increased viscosity, and altered intravitreal distribution dynamics, offering the potential for extended treatment intervals
Intravitreal Bevacizumab for Choroidal Neovascularization due to Pathological Myopia: Long-term Outcomes
No full text- …
